GTx and Merck & Co. have agreed to terminate an exclusive license and collaboration agreement effective immediately, GTx said in a regulatory filing. GTx will now not receive any of the future milestone payments or royalties of up to $422 million that it was eligible to receive under the deal, the company said in a filing with the U.S. Securities and Exchange Commission.

The collaboration agreement, dated Nov. 5, 2007, was related to the development and commercialization of selective androgen receptor modulators (SARM) compounds, GTx said.